Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK

Anne Hilgendorff,1 Christian Apitz,2 Damien Bonnet,3 Georg Hansmann4

ABSTRACT
Persistent pulmonary hypertension of the newborn (PPHN) is the most common neonatal form and mostly reversible after a few days with improvement of the underlying pulmonary condition. When pulmonary hypertension (PH) persists despite adequate treatment, the severity of parenchymal lung disease should be assessed by chest CT. Pulmonary vein stenosis may need to be ruled out by cardiac catheterisation and lung biopsy, and genetic workup is necessary when alveolar capillary dysplasia is suspected. In PPHN, optimisation of the cardiopulmonary situation including surfactant therapy should aim for preductal SpO2 between 91% and 95% and severe cases without post-tricuspid-unrestrictive shunt may require prostaglandin E1 to maintain ductal patency in right heart failure. Inhaled nitric oxide is indicated in mechanically ventilated infants to reduce the need for extracorporeal membrane oxygenation (ECMO), and sildenafil can be considered when this therapy is not available. ECMO may be indicated according to the ELSO guidelines. In older preterm infant, where PH is mainly associated with bronchopulmonary dysplasia (BPD) or in term infants with developmental lung anomalies such as congenital diaphragmatic hernia or cardiac anomalies, left ventricular diastolic dysfunction/left atrial hypertension or pulmonary vein stenosis, can add to the complexity of the disease. Here, oral or intravenous sildenafil should be considered for PH treatment in BPD, the latter for critically ill patients. Furthermore, prostanoids, mineralocorticoid receptor antagonists, and diuretics can be beneficial. Infants with proven or suspected PH should receive close follow-up, including preductal/postductal SpO2 measurements, echocardiography and laboratory work-up including NT-proBNP, guided by clinical improvement or lack thereof.

INTRODUCTION
Pulmonary hypertension (PH), especially in the neonate, is a syndrome with multiple possible aetiologies, leading to challenges in its management. In the newborn, persistent pulmonary hypertension of the newborn (PPHN; PH group 1) is mostly associated with pulmonary or systemic conditions leading to acute respiratory failure. In the preterm infant, PH mainly occurs with chronic lung disease (CLD) where impaired vascular growth and function results from prenatal and postnatal injuries. Likewise, other developmental lung anomalies such as congenital diaphragmatic hernia (CDH) can be associated with PH. Both, the heterogeneity of the disease mechanisms and the lack of evidence from clinical trials limit the availability of standardised treatment regimens. Long-term outcome in infants with PH is largely unknown. Here, we discuss different pathophysiological aspects of PH in the preterm and term neonate with acute or chronic lung disease, and presents expert consensus recommendations on diagnostic and therapeutic approaches.

CLASSIFICATION
As a modification of the Dana Point classification1 the Nice World Symposium classification of PH2 now emphasises different conditions of the lungs arising in the neonatal period associated with the development of PH. First, PPHN due to its particular anatomical and physiological nature forms a separate subcategory in group 1 "pulmonary arterial hypertension". Second, group 3 "pulmonary hypertension due to lung diseases and/or hypoxia" now comprises a subcategory ‘developmental lung diseases’. In this category, different disease entities are summarised resulting from abnormalities of the alveolar and vascular compartment or the connective tissue as a consequence of early pre or postnatal injury mechanisms impacting on lung developmental processes (table 1).

METHODS
The recommendations of this expert consensus statement are given in table 1. The recommendations relate to the grading system currently suggested by the European Society of Cardiology (ESC) and the American Heart Association (AHA), and were based on data derived from paediatric studies only (class, level of evidence). The grading and voting process within the writing group is outlined in the executive summary of this online supplement.24 Computerised searches of the PubMed/MEDLINE bibliographic database from January 1990 to July 2015 were conducted. The developer searched using the terms ‘pediatric pulmonary hypertension’, ‘pulmonary hypertension’, ‘neonate’, ‘neonatal chronic lung disease’, ‘bronchopulmonary dysplasia’, ‘congenital diaphragmatic hernia’, ‘nitric oxide’, ‘sildenafil’.

For numbered affiliations see end of article.

Correspondence to Dr Anne Hilgendorff, Department of Neonatology, Perinatal Center Grosshadern, Ludwig-Maximilians University, Munich, Germany and Comprehensive Pneumology Center, University Hospital of the University of Munich and Helmholtz Zentrum Muenchen, Munich, Germany Member of the German Lung Research Center (DZL) anne.hilgendorff@med.uni-muenchen.de or Prof. Dr. Georg Hansmann; georg.hansmann@gmail.com

This article is a product of the writing group of the European Paediatric Pulmonary Vascular Disease Network (Writing Group Chair: G Hansmann, Writing Group Co-Chair: C. Apitz); DGPK, German Society of Paediatric Cardiology; ISHLT, International Society of Heart and Lung Transplantation.

Received 22 August 2015
Revised 29 September 2015
Accepted 14 October 2015

To cite: Hilgendorff A, Apitz C, Bonnet D, et al Heat 2016;102:ii49–ii56.
BACKGROUND ON PH IN THE NEONATE AND INFANT

We focused on expert consensus statements referring to the most common and most relevant clinical scenarios associated with PH in the neonate and infant: PPHN (here defined as PH with failed postnatal decrease in pulmonary vascular resistance (PVR)), PH associated with CDH/lung hypoplasia, and PH in bronchopulmonary dysplasia (BPD)/neonatal CLD (nCLD).

The consequence of the first breaths after birth aiming at establishing functional residual capacity of the lungs is an acute drop of PVR that allows a subsequent 8-fold to 10-fold increase in pulmonary blood flow, essential for postnatal gas-exchange through the lungs. If this physiological adaptation fails, PPHN can develop.

PPHN as a disease of failed postnatal transition with persistently high PVR and pulmonary arterial pressure (PAP) has been estimated to occur in 2 per 1000 of live born infants. Others have defined PPHN as a disease occurring during the first 30 days of life usually presenting at or within a few days after birth.

Regardless of the definition, the diagnostic evaluation of any neonate presenting with symptomatic PH outside the first week of life is critical as the aetiology is likely to exceed the classical PPHN diagnosis. Chronic progressive PH in the first year of life is now known to be a distinct condition that is even less well understood than PPHN, and may occur or worsen with or without a preceding PPHN episode. This disease can resemble idiopathic PAH of infancy, which tends to have a poor prognosis.

PH frequently complicates the course of neonates with respiratory failure. Known risk factors for the development of PPHN are (elective) caesarean delivery, meconium aspiration syndrome, severe respiratory distress due to primary surfactant deficiency in the preterm infant and sepsis. It can occur without any perinatal risk factor, but is known to complicate the course of congenital heart diseases. The role of maternal 

Table 1

| Recommendations | COR | LOE |
|-----------------|-----|-----|
| For the treatment of PH in the NICU, the term or preterm newborn infant should receive oxygen, ventilatory support and/or surfactant if needed to achieve a pO2 between 91% and 95% when PH is suspected or established; lung hyperinflation and atelectasis, or lung collapse and intermittent desaturations below 85%, or hyperoxia with preductal pO2 above 97% should be avoided2,3 | I | A |
| In a newborn infant with acute PPHN in the first hours after birth, a pO2 between 45 and 60 mm Hg and a target pH >7.25 with lactate <5 mmol/L can be considered as target values.4,5 | Ila | B |
| The preterm and term neonate with severe PH (PPHN) and no post-tricuspid-unrestrictive shunt (e.g. no VSD) may receive Prostaglandin E (PGE) 1 or PGE2 to maintain ductal patency in right heart failure6 | Ila | B |
| ECMO can currently not be recommended for the preterm infant <34 0/7 gestational weeks p.m. and/or <2000g body weight, with severe PH8 | III | B |
| The preterm infant with respiratory failure should not receive iNO for the prevention of BPD and associated PH, if not enrolled in a rigorously conducted randomised clinical trial9 | III | A |
| iNO is indicated for treatment of PPHN in mechanically ventilated newborns to improve oxygenation and to reduce the need for ECMO (a) if FiO2 is less than 100% Hg (while receiving 100% oxygen), or (b) if the oxygen index exceeds 2510 | I | A |
| Oral sildenafil should be considered for treatment of PPHN and PH in BPD, especially if iNO is not available11 | Ila | B |
| Intravenous sildenafil may be considered for treatment of PH, including PPHN, in critically ill patients, especially in those with an unsatisfactory response to iNO12,13 | IIb | B |
| In the neonate with PPHN or BPD, intravenous prostanooids through a dedicated central line or inhaled iloprost, can be beneficial14 | Ila | B |
| Treatment of severe PPHN may be extended to ECMO if other intensive care measures fail (http://www.elso.org)8 | Ila | B |
| In infants with severe BPD with or without PH, treatment with diuretics, that is, hydrochlorothiazide and spironolactone, can be considered, as long as cardiac preload is adequate15,16 | Ila | B |
| All infants with proven or suspected PH should receive close follow up, including preductal/postductal SpO2 measurements, echocardiography (one per/week initially, then 1–2/month), and laboratory work-up depending on disease severity including NT-proBNP, BNP, troponin optional, guided by clinical improvement or lack thereof17–23 | I | C |

Recommendations relate to the grading system suggested by the European Society of Cardiology (ESC) and the American Heart Association (AHA), data derived from paediatric studies only (class, level of evidence).

PBD, bronchopulmonary dysplasia; CLD, chronic lung disease; nCLD, neonatal CLD; COR, class of recommendation; ECMO, extracorporeal membrane oxygenation; iNO, inhaled nitric oxide; LOE, levels of evidence; PH, pulmonary hypertension; PPHN, persistent pulmonary hypertension of the newborn.
Although PH predominantly develops in the very low birth weight and very preterm infant, some infants develop late onset PH after a couple of weeks. Furthermore, the moderate but growth-retarded preterm infant has been shown to develop PH in a considerable number of cases. A crucial and unresolved question in neonates and infants with BPD is the optimal time for PH screening by echocardiography. At the same time, the best diagnostic tool to detect PH in patients with BPD is still a matter of debate, as the non-invasive evaluation by echocardiography has been shown to lack sensitivity compared with the invasive procedure of cardiac catheterisation in these patients. Finally, the prediction of late PH by the presence of early disease in the preterm infant is still questionable. Certainly, patients with BPD with late PH need careful evaluation and a minimisation of hypoxic episodes. Furthermore, the persistence of PH in these and other patients should lead to the consideration of cardiac catheterisation and specific imaging techniques, that is, CT and/or cardiac MRI to rule out pulmonary vein stenosis. It has to be considered that pulmonary capillary haemangiomatosis (PH group 1) may be diagnosed at a wide age range, and may clinically be indistinguishable from pulmonary veno-occlusive disease (PH group 1) or PAH (PH group 1).

### Prognosis and outcome of PH in BPD/nCLD
Approximately one in four infants with moderate-to-severe BPD is known to develop PH, triggered by the complex interplay of inflammatory processes, stretch and oxygen toxicity side-by-side with recurrent alveolar hypoxia leading to endothelial dysfunction. The development of PH in BPD is not only an epiphrenomenon or minor secondary event, but appears to greatly increase mortality with an estimated death rate of 47% 2 years after PH diagnosis. Furthermore, with an increasing percentage of extremely immature infants surviving in the post-surfactant era, BPD is one of the most common primary diagnoses in neonatal follow-up care and frequently seen in paediatric PH clinics today. BPD as a major etiologic factor for PH

### Table 2 Developmental lung diseases associated with pulmonary hypertension

| Developmental defect          | Vascular pathology                                                                 |
|-------------------------------|----------------------------------------------------------------------------------|
| Alveolar capillary dysplasia (ACD) with or without misalignments of veins (MPV) | Genetic disorder associated with an abnormal development of the capillary vascular system around the alveoli of the lungs |
| Bronchopulmonary dysplasia (BPD) | Prenatal and postnatal impact of exogenous risk factors on a structural and functional immature lung lead to postnatal impairment of angiogenesis and alveolarisation associated with abnormal vascular function (increased tone, altered reactivity, impaired metabolism) and structure (smooth muscle cell proliferation, altered extra cellular matrix structure) |
| Congenital diaphragmatic hernia | Developmental defect leading to severe vascular remodelling and rarefaction of the vascular bed |
| Lung hypoplasia (primary and secondary) | Genetic abnormalities or severe reduction in amniotic fluid leading to reduced prenatal alveolar and vascular development |
| Pulmonary interstitial glycosis | Rare non-lethal paediatric form of interstitial lung disease, possible male predominance. Infants present with respiratory distress. Histological characteristics are the accumulation of monoparticulate glycogen in interstitial cells and associated lung growth abnormalities affecting all lung structures |
| Pulmonary alveolar proteinosis | Rare lung disease in which abnormal accumulation of surfactant occurs within the alveoli, interfering with gas exchange and affecting lung growth. Possible cause anti-GM-CSF autoantibodies |
| Pulmonary lymphangiectasia     | Rare developmental pulmonary disorder characterised by pulmonary subpleural, interlobar, perivascular and peribronchial lymphatic dilatation |
| Surfactant protein (SP) abnormalities (SP-B and SP-C deficiency, ATP binding cassette A3 mutation, thyroid transcription factor 1/Nkx2.1 homeobox mutation) | Genetic inheritance of surfactant deficiency leading to impaired lung development |
development has been recognised and, in fact, was assigned its own category in the recently published classification of paediatric pulmonary hypertensive vascular disease (category 4: BPD; PVRI Panama classification, 2011).26

DIAGNOSIS AND MONITORING OF PH ASSOCIATED WITH ACUTE OR CHRONIC LUNG DISEASE IN THE PRETERM AND TERM NEONATE AND INFANT

Diagnosis and monitoring of existing or developing PH is critical in PPHN as well as in PH associated with developmental/parenchymal lung diseases. High resolution chest CT with angiography is a key non-invasive diagnostic tool for assessing the underlying lung disease beyond chest X-ray41 and needs to be considered in cases where other diagnostic tools do not suffice. Regarding the diagnosis of PH by echocardiography and catheterisation we refer to other publications in this special issue.42 43

In general, transthoracic echocardiography should be performed initially and once or twice per month in all infants with clinical suspicion of PH. The latter is fulfilled with increased oxygen requirement or hypoxaemia, gradual increase in ventilator settings or oxygen requirement and clinical signs of RV dysfunction. In infants treated for acute PH or undergoing weaning from PH, echocardiography should be pursued twice a week in combination with serum BNP/NT-proBNP. In infants with BPD after discharge, regular or continuous measurements of oxygen saturation should accompany oxygen weaning in infants with BPD, at the upper and lower extremities. Echocardiography should be performed (a) every 3 months in infants with BPD in need of additional oxygen supply or those at strong risk for PH; (b) every 3–6 months in children at risk, that is, infants with growth retardation, very low birth weight, MV/CPAP >28th day of life, BPD, failure to thrive despite adequate caloric intake. Cardiac MRI can be considered, if available and if strong clinical suspicion for PH with ventricular dysfunction is present. Serum BNP or NT-proBNP are frequently used as monitoring and outcome biomarkers for children with diagnosed PH, but increased concentrations due to high systemic blood pressure, and outcome biomarkers for children with diagnosed PH, but increased concentrations due to high systemic blood pressure, persistent ductus arteriosus (PDA), renal failure, or left ventricular dysfunction can be a confounder. All infants with persistent PH despite optimal management of lung disease, before starting chronic pulmonary vasodilator therapy, should probably undergo cardiac catheterisation,3 22 23 40 unless clinical circumstances skew the risk-benefit ratio.

THERAPY OF PH ASSOCIATED WITH ACUTE OR CHRONIC LUNG DISEASE IN THE PRETERM AND TERM NEONATE AND INFANT

General treatment measures for PPHN in the term and preterm neonate

Usually, the course of PPHN is favourable. First, exposure to environmental factors that worsen PPHN including handling, tracheal suction, heel pricks and others have to be minimised or avoided, if possible. Furthermore, polycythaemia increasing blood viscosity and increased PVR should be corrected (figure 1).

Mechanical ventilation strategies need to aim for adequate lung recruitment and alveolar ventilation by avoiding overinflation of the lungs as well as high mean airway pressures to prevent both, pulmonary barotrauma and volutrauma. The goal is to maintain preductal SaO2 over 85%, and PaCO2 in the range of 40–55 mm Hg. Optimisation of the acid-base balance (pH range 7.45–7.55) to control PVR may require repetitive doses of sodium bicarbonate, although this therapy needs to be considered with caution due to its known side effects and limitations. Furthermore, appropriate fluid management, cardiovascular resuscitation and use of pulmonary vasodilators should be considered (5). Supporting cardiovascular function remains a major goal in PPHN management. Early initiation of inotropic and vasoactive agents to increase cardiac output, maintain adequate blood pressure and enhance oxygen delivery to the tissue is preferred.

The application of the locally vasodilative inhaled nitric oxide (iNO) is the mainstay of PPHN therapy in most cases. Intravenous vasodilators such as epoprostenol and treprostinil may be considered and should be given through a central venous line of the upper body, but can worsen the clinical condition by creating V/Q mismatch and intrapulmonary shunt resulting in profound desaturations. In all cases, a rigorous clinical and echocardiographic assessment is required for diagnosis and monitoring of biventricular systolic and diastolic function.

Pharmacological and extracorporeal membrane oxygenation treatment for PPHN

Infants with significant right-to-left shunting require pulmonary vasodilator therapy. iNO is presently recommended for infants with PPHN12 as it improves outcome in the hypoxic term and near term infant by reducing the incidence of the combined endpoint death or need for extracorporeal membrane oxygenation (ECMO). Oxygenation improves in approximately 50% of infants receiving iNO.12 Usual concentrations of iNO range from 5 to 20 ppm to treat PPHN, with the typical starting dose being 20 ppm. As a preventive measure for the development of acute or chronic PH in the preterm infant with respiratory failure, the use of iNO cannot be recommended outside randomised controlled trials.9 10 In patients with CDH, iNO may be considered for bridging to ECMO (oxygenation index ≥20 or saturation differences >10%; oxygenation index (O2; FiO2×MAP/pO2) although no beneficial effects could be shown for this patient cohort.44

ECMO may be required to ensure effective oxygenation and decarboxylation while limiting barotrauma and volutrauma of the lung and to improve right heart failure. ECMO is indicated when hypoxaemia persists in spite of optimal medical management according to the following criteria:

- Preductal SpO2 <85% despite peak inspiratory pressure >28 cmH2O (or mean airway pressure >15 cmH2O with high frequency oscillation),
- PPHN and circulatory failure resistant to adequate management,
- Gestational age >34 weeks,
- Birth weight >2 kg.

Additional ECMO criteria have been proposed with consistent OI ≥40, systemic hypotension resistant to fluid and inotropic therapy, urine output <0.05 mL/kg/h for 12–24 h and metabolic acidosis (lactate ≥5 mmol/L, pH <7.15). See also the ELSO guidelines for ECMO.15

There is limited experience for the application of systemic medication used in PAH in patients with PPHN. Phosphodiesterase-5 (PDE-5) inhibitors such as sildenafil may be potentially useful as an increase in PDE-5 activity contributes to the pathophysiology of PPHN. Evidence exists that sildenafil is well tolerated in the newborn with PPHN.14 It is applied via feeding tube in a starting dose of 0.5–1 mg/kg/dose every 6 h.46–48 64 Meta-analysis of three trials including 77 newborns with PPHN indicated that sildenafil may improve oxygenation and reduce mortality.14 These results suggest that sildenafil has significant potential for PPHN treatment, especially in settings

Hilgendorff A, et al. Heart 2016;102:i549–i556. doi:10.1136/heartjnl-2015-308591

Published online October 20, 2016.
where iNO is not available. Nonetheless, systemic pulmonary vasodilator treatment has to be considered with caution as worsening of the ventilation-perfusion mismatch hypoxia and systemic hypotension may occur, especially in the preterm infant. In CDH, intravenous sildenafil can be considered in case of suprasystemic PAP and right-to-left shunting. Prostacyclin and analogues have been used in PPHN but evidence is limited as only a few case reports or short series are available.

Figure 1 Algorithm with the current recommendations for the diagnosis, monitoring and treatment of persistent pulmonary hypertension of the newborn (PPHN). PH needs to be considered when tricuspid regurgitation (TR) jet >2.5 m/sec (Echo) and preductal/postductal oxygen saturation differences >10%. ECMO, extracorporeal membrane oxygenation; iNO, inhaled nitric oxide; PGE1, prostaglandin E1; PPHN, pulmonary hypertension of the newborn; RV, right ventricle; TR, tricuspid regurgitation.

Hilgendorf A, et al. Heart 2016;102:i49–i56. doi:10.1136/heartjnl-2015-308591
available. The use of epoprostenol in term and preterm infants requires a central line and careful management of systemic effects.\(^{50}\)

Finally, there is increasing evidence that endothelins contribute to PH in the neonate. Although, recent case reports and earlier studies suggest that bosentan may improve PPHN, there is still insufficient evidence to generally recommend the use of bosentan to manage PPHN.\(^{51,52}\) The yet unpublished FUTURE4 trial on bosentan in PPHN showed negative results, may be due to poor intestinal resorption of oral bosentan in neonates.

In the case of imminent RV failure, the (re-) opening of the ductus arteriosus by the use of prostaglandin E1 (PGE1) or even stenting of the persistent ductus arteriosus (PDA) may be considered to decompress the RV leading to a decrease in SaO2 measured in the lower extremities.\(^{53}\) Figure 1 provides a schematic overview over treatment and monitoring measures in the infant with PPHN.

**Treatment of chronic PH in BPD/nCLD**

Supplemental oxygen therapy is the common treatment option for PH associated with BPD/nCLD where target systemic arterial oxygen saturation is >93% for all premature infants and >95% for infants with proven PH (Figure 2). Serial echocardiograms and cardiac catheterisation is recommended to determine PAP and PVR.\(^{4}\) Atrial or ventricular shunts are not well tolerated in children with nCLD and may be related to the smaller vascular surface area in relation to body size and cardiac output, where a mild increase in pulmonary blood flow may indicate a significant shunt.\(^{4}\)

**Figure 2** Algorithm with the current recommendations for the management of pulmonary hypertension in the newborn with bronchopulmonary dysplasia (BPD)/neonatal chronic lung disease (nCLD).
In infants with severe BPD, treatment with diuretics, that is, hydrochlorothiazide and spironolactone can be considered, especially when volume overload is evident. Spironolactone may have additional benefits in neonates and young infants due to mineralocorticoid blockade in RV hypertrophy and PH and can improve lung mechanics in BPD. \(^{35}\)

Pulmonary vasodilators/PAH specific medication

Long-term therapy may be considered after careful evaluation and exclusion of associated anomalies such as a left-to-right shunt, left ventricular diastolic dysfunction and pulmonary vein stenosis. However, published data do not provide sufficient evidence to allow for general recommendations. Therefore, careful considerations for the use of targeted therapeutic approaches together with consequent and timely re-evaluations are advised. It has to be noted that all PAH-targeted drugs have to be declared ‘off-label use’ in the neonate and infant with PH associated with BPD/nCLD.

Of the three current potential target pathways for PH treatment in BPD/nCLD, the widest experience is reported for the modulation of the NO signalling pathway with the PDE-5-inhibitor sildenafil. With oral sildenafil, significant improvement of PAP could be demonstrated in children under the age of 2 years with nCLD and PH. \(^{66}\) Intravenous sildenafil may be advantageous in sick infants when enteral bioavailability is unclear. Furthermore, repetitive (or potentially continuous) application of inhaled iloprost can be used in patients with BPD. \(^{57-59}\) As endothelin is a potent pulmonary vasoconstrictor and increased in BPD and hyperoxia, \(^{31}\) bosentan treatment may also be considered in PH associated with BPD/nCLD, although only case reports are available for these infants. \(^{60-62}\) Very potent intravenous vasodilators, such as epoprostenol or treprostinil, can be considered but need to be given through a central venous line (upper body line preferred). Their use may be limited due to the adverse effects with systemic hypotension, potential V/Q mismatch and intrapulmonary right-to-left shunting with consecutive hypoxaemia. Figures 1 and 2 provide schematic overviews over treatment and monitoring measures in the infant with PPHN or PH in BPD/nCCCD. Over the current recommendations for the treatment of pulmonary hypertension (PH) in chronic lung disease of the preterm and term infant.

CONCLUSIONS

PPHN is a condition in term neonates that may or may not have prenatal origins, and often complicates acute respiratory failure in the first 1–2 weeks after birth. As the course of the disease can be extremely severe, rigorous treatment regimens is mandatory to improve disease outcome. Since iNO and ECMO are effective in the majority of the cases and only limited evidence for the efficacy of oral or intravenous medications for PPHN treatment is available, the importance of any additional, so-called ‘PH specific’ medication in the armamentarium for PH treatment needs to be defined for this patient cohort. In the preterm infant, PH is rare in the first 4 weeks of postnatal life, but may develop along with nCLD, that is, BPD, where vascular dysfunction and alveolar hypoxia perpetuate disease development. Management of PH in developmental lung diseases is mainly focused on the optimisation of systemic oxygenation. Evidence is still lacking for the use of medications available for pulmonary arterial hypertension treatment in the neonatal or former preterm cohort. Thus, a thorough evaluation of PH and its underlying mechanisms is mandatory before targeted PH therapy on a case-by-case basis. Long-term outcome related to PPHN and PH associated with developmental lung diseases remains mostly unknown, pointing to the need for prospective and controlled studies in population-based cohorts.

Author affiliations

1Department of Neonatology, Dr von Haunersche Children’s Hospital, Ludwig-Maximilians University, Munich, Germany
2Department of Paediatric Cardiology, Children’s Hospital, University of Ulm, Ulm, Germany
3Unité Médico-Chirurgicale de Cardiologie Congénitale et Pédiatrique, Centre de référence Malformations Cardiaques Congénitales Complexes—M3C, Hôpital Necker Enfants Malades, APHP, Université Paris Descartes, Sorbonne Paris, Paris, France
4Department of Paediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany.

Funding AH receives grant support from the Helmholtz Gemeinschaft, the Helmholtz Zentrum München, Germany and the German Center for Lung Research (DZL). CA currently receives grant funding from Stiftung Kinderherz (2511-10-13-001) and Behring-Röntgen-Stiftung (59-0018). DB received grants from the Agence Nationale de la Recherche and from the Fédération Française de Cardiologie. GH currently receives grant support from the German Research Foundation (DFG; HA 4348/2-1), Fördergemeinschaft deutsche Kinderherzzentren (W-H-001-2014), and Stiftung Kinderherz (2511-6-13-011).

This Heart supplement was produced with support from an unrestricted educational grant from Actelion Pharmaceuticals Germany GmbH, Bayer Pharma AG, and Pfizer Inc. None of these organisations had any influence on the composition of the writing group or the content of the articles published in this supplement. Open Access publication of this article was sponsored by Actelion Pharmaceuticals Germany GmbH.

Competing interests DB received fees for consulting, advisory boards and steering committee memberships from Actelion Pharmaceuticals, Eillilly, Pfizer and Bayer.

Provenance and peer review Commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

1 Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:1 Suppl:S43–54.
2 Ivy DD, Abman SH, Bart RS, et al. Paediatric pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D117–26.
3 Ambalavanan N, Mourani P. Pulmonary hypertension in bronchopulmonary dysplasia. Birth Defects Res 2014;100:240–6.
4 Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 2002;87:F15–18.
5 Castillo A, Sola A, Baquero H, et al. Pulse oxygen saturation levels and arterial oxygen tension values in newborns receiving oxygen therapy in the neonatal intensive care unit: is 85% to 93% an acceptable range? Paediatrics 2008;121:882–9.
6 Mourani PM, Ivy DD, Tao D, et al. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2004;170:1006–13.
7 Teng RJ, Wu TL. Persistent pulmonary hypertension of the newborn. J Famos Med Assoc 2013;112:177–84.
8 Organization ELS. ELSO guidelines for neonatal respiratory failure. Ann Arbor, MI, 2013; Version 1.3 December 2013.
9 Donohue PH, Gilmore MM, Cristofalo E, et al. Inhaled nitric oxide in preterm infants: a systematic review. Paediatrics 2011;127:e414–22.
10 Askie LM, Ballard RA, Cutter GR, et al. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. Paediatrics 2011;128:729–39.
11 Kinsella JP, Cutter GR, Steinhorn RH, et al. Noninvasive inhaled nitric oxide does not prevent bronchopulmonary dysplasia in premature newborns. J Pediatr 2014;165:1104–8, e1.
12 Finer NN, Barrington KL. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006;(4):CD003399.
13 Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev 2011;(8):CD005949.
Pulmonary vascular disease

14 Steinhorner RH, Kinsella JP, Pierce C, et al. Intrauterine sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009;155:841–7.e1.
15 Fraisse A, Butrous G, Taylor MB, et al. Intrauterine sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. Intensive Care Med 2011;37:502–9.
16 Brown AT, Gillespie JL, Miquel-Verges F, et al. Inhaled epoprostenol therapy for pulmonary hypertension: improves oxygenation index more consistently in neonates than in older children. Pulm Circ 2012;2:61–6.
17 Eronen M, Pohjarevi M, Andersson S, et al. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol 1997;18:3–7.
18 McIntyre CM, Hanna BD, Rintoul N, et al. Safety of epoprostenol and treprostinil in children less than 2 months of age. Pulm Circ 2013;3:862–9.
19 Rugolotto S, Beghini R, Cogo I, et al. Epoprostenol for very low birth weight (VLBW) infants: a novel dilution protocol. Pediatr Med Chir 2013;35:223–4.
20 Maron BA, Leopold JA. Emerging concepts in the molecular basis of pulmonary vascular disease. Circulation 2015;131:2079–91.
21 Brion JP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002;(1):CD001817.
22 Berkelhamer SK, Mestan KK, Steinhorh RH. Pulmonary hypertension in bronchopulmonary dysplasia. Semin Perinatol 2013;37:124–31.
23 Cuna A, Kandasamy J, Sims B. B-type natriuretic peptide and mortality in extremely low birth weight infants with pulmonary hypertension: a retrospective cohort analysis. BMC Pediatr 2014;14:68.
24 Hansmann G, Abdul-Khalil H, Alastalo TP, et al. Executive Summary. Consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016;102:i23–9.
25 Kinsella JP. Inhaled nitric oxide in the term newborn. Early Hum Dev 2008;84:709–16.
26 Maron BA, Waxman AB, Opotowsky AR, et al. Hemodynamic and pulmonary changes following surgical creation of a diaphragmatic hernia in fetal lambs. Korean Circ J 2013;93:613–17.
27 Altmann SH, Kinsella JP, Rosserzweig EB, et al. Implications of the US. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension. Am J Respir Crit Care Med 2013;187:52–5.
28 Oishi P, Datar SA, Fineman JR. Advances in the management of pediatric pulmonary hypertension. Pediatr Pulmonol 2003;36:529–35.
29 Wardle AJ, Wardle R, Lyut K, et al. The utility of sildenafil in pulmonary hypertension of the newborn: a review. Pediatr Pulmonol 2010;45:569–76.
30 Brion JP, Primhak RA, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2002;(1):CD001817.
31 Licht C, Schickendantz S, Sreeram N, et al. Safety of epoprostenol in neonates with persistent pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016;102:i23–9.
32 Singh SA, Ibrahim T, Clark DJ, et al. Pulmonary hypertension in formerly premature infants with bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed 2009;94:195–7.
33 Mestan KK, Check J, Minturn L, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Circulation 2014;130:A13503.
34 Gupta N, Kamlin CO, Cheung M, et al. Prostaglandin E1 use during neonatal transfer: potential beneficial role in persistent pulmonary hypertension of the newborn. Arch Dis Child Fetal Neonatal Ed 2013;98:F186–8.
35 Stewart A, Brion JP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev 2011(9):CD001817.
36 Maron BA, Waxman AB, Oprotovsky AR, et al. Effectiveness of spironolactone plus ambrisentan for treatment of pulmonary arterial hypertension (from the [ARES] study 1 and 2 trials). Am J Cardiol 2013;112:720–5.
37 Morani PM, Sontag MK, Ivy DD, et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:579–84. 81.e1–2.
38 Gürakan Y, Kayiran P, Oztrick N, et al. Therapeutic combination of sildenafil and iloprost in a preterm neonate with pulmonary hypertension. Pediatr Pulmonol 2011;46:617–20.
39 Hwang SK, O YC, Kim NS, et al. Use of inhaled iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension. Korean Circ J 2009;39:343–5.
40 Pasqua M, De Luca D, De Carolis MP, et al. Nebulized iloprost and noninvasive respiratory support for impending hypoxaemic respiratory failure in formerly preterm infants: a case series. Pediatr Pulmonol 2012;47:757–62.
41 An HS, Bae EJ, Kim GB, et al. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J 2010;40:131–6.
42 Papoff P, Cesario C, Caresta E, et al. Current strategies for treating infants with severe pulmonary hypertension. J Matern Fetal Neonatal Med 2012;25(Suppl 3):15–20.
43 Krishnan U, Krishna S, Gewitz M. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol 2008;29:1082–6.
44 Rugolotto S, Erroco G, Beghini R, et al. Wearing of epoprostenol in a small infant receiving concurrent bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia. Minerva Pediatr 2006;58:491–4.
45 Hansmann G, Apitz C. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016;102:i67–85.